538 related articles for article (PubMed ID: 31526130)
21. Nectin-4: a Novel Therapeutic Target for Skin Cancers.
Hashimoto H; Tanaka Y; Murata M; Ito T
Curr Treat Options Oncol; 2022 Apr; 23(4):578-593. PubMed ID: 35312963
[TBL] [Abstract][Full Text] [Related]
22. Enfortumab Vedotin in urothelial cancer.
Alt M; Stecca C; Tobin S; Jiang DM; Sridhar SS
Ther Adv Urol; 2020; 12():1756287220980192. PubMed ID: 33447264
[TBL] [Abstract][Full Text] [Related]
23. Cutaneous toxicity associated with enfortumab vedotin treatment of metastatic urothelial carcinoma.
Wu S; Adamson AS
Dermatol Online J; 2019 Feb; 25(2):. PubMed ID: 30865407
[TBL] [Abstract][Full Text] [Related]
24. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.
Challita-Eid PM; Satpayev D; Yang P; An Z; Morrison K; Shostak Y; Raitano A; Nadell R; Liu W; Lortie DR; Capo L; Verlinsky A; Leavitt M; Malik F; Aviña H; Guevara CI; Dinh N; Karki S; Anand BS; Pereira DS; Joseph IB; Doñate F; Morrison K; Stover DR
Cancer Res; 2016 May; 76(10):3003-13. PubMed ID: 27013195
[TBL] [Abstract][Full Text] [Related]
25. Enfortumab Vedotin: Nursing Perspectives on the Management of Adverse Events in Patients With Locally Advanced or Metastatic Urothelial Carcinoma.
Pace A; Brower B; Conway D; Leis D
Clin J Oncol Nurs; 2021 Apr; 25(2):E1-E9. PubMed ID: 33739346
[TBL] [Abstract][Full Text] [Related]
26. An update on antibody-drug conjugates in urothelial carcinoma: state of the art strategies and what comes next.
D'Angelo A; Chapman R; Sirico M; Sobhani N; Catalano M; Mini E; Roviello G
Cancer Chemother Pharmacol; 2022 Sep; 90(3):191-205. PubMed ID: 35953604
[TBL] [Abstract][Full Text] [Related]
27. Emerging agents for the treatment of metastatic urothelial cancer.
Kwon WA; Seo HK
Investig Clin Urol; 2021 May; 62(3):243-255. PubMed ID: 33943047
[TBL] [Abstract][Full Text] [Related]
28. Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin.
Jain RK; Skelton WP; Zhang J
Cancer Manag Res; 2020; 12():8379-8386. PubMed ID: 32982431
[TBL] [Abstract][Full Text] [Related]
29. Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside.
Ungaro A; Tucci M; Audisio A; Di Prima L; Pisano C; Turco F; Delcuratolo MD; Di Maio M; Scagliotti GV; Buttigliero C
Cells; 2022 Feb; 11(5):. PubMed ID: 35269424
[TBL] [Abstract][Full Text] [Related]
30. Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy.
Tassinari E; Mollica V; Nuvola G; Marchetti A; Rosellini M; Massari F
Cancer Manag Res; 2022; 14():1945-1960. PubMed ID: 35720644
[TBL] [Abstract][Full Text] [Related]
31. [Antibody-drug conjugates directed against NECTIN-4 as a new treatment option for patients with metastatic urothelial carcinoma].
Klümper N; Eckstein M; Kunath F; Heidegger I; Becker C; Rausch S;
Urologie; 2023 Nov; 62(11):1193-1199. PubMed ID: 37658236
[TBL] [Abstract][Full Text] [Related]
32. Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
Maiorano BA; Catalano M; Maiello E; Roviello G
Front Oncol; 2023; 13():1254906. PubMed ID: 37781180
[TBL] [Abstract][Full Text] [Related]
33. Use of enfortumab vedotin in an HIV-positive patient with urothelial carcinoma.
Azizi A; Houshyar R; Mar N
J Oncol Pharm Pract; 2022 Jul; 28(5):1226-1229. PubMed ID: 35043748
[TBL] [Abstract][Full Text] [Related]
34. Severe eczematoid and lichenoid eruption with full-thickness epidermal necrosis developing from metastatic urothelial cancer treated with enfortumab vedotin.
Sasaki R; Fujimura T; Lyu C; Aiba S
J Dermatol; 2020 Dec; 47(12):1436-1438. PubMed ID: 32860247
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review.
Padua TC; Moschini M; Martini A; Pederzoli F; Nocera L; Marandino L; Raggi D; Briganti A; Montorsi F; Necchi A
Urol Oncol; 2022 Oct; 40(10):413-423. PubMed ID: 35973928
[TBL] [Abstract][Full Text] [Related]
36. The role of enfortumab vedotin and sacituzumab govitecan in treatment of advanced bladder cancer.
Hanna KS; Larson S; Nguyen J; Boudreau J; Bulin J; Rolf M
Am J Health Syst Pharm; 2022 Apr; 79(8):629-635. PubMed ID: 34864835
[TBL] [Abstract][Full Text] [Related]
37. [New paradigms in the second line treatment for advanced and metastatic urothelial carcinoma.].
Vidal N; Puente J
Arch Esp Urol; 2020 Dec; 73(10):1007-1015. PubMed ID: 33269719
[TBL] [Abstract][Full Text] [Related]
38. New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer - What do we understand so far?
Hoffman-Censits J; Lombardo K; McConkey D; Hahn NM; Bashir B; Kelly WK; Johnson B; Matoso A
Urol Oncol; 2021 Oct; 39(10):619-622. PubMed ID: 34148797
[TBL] [Abstract][Full Text] [Related]
39. Current Therapy for Metastatic Urothelial Carcinoma.
Nadal R; Clara JA; Valderrama BP; Bellmunt J
Hematol Oncol Clin North Am; 2021 Jun; 35(3):469-493. PubMed ID: 33958146
[TBL] [Abstract][Full Text] [Related]
40. Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.
Klümper N; Ralser DJ; Ellinger J; Roghmann F; Albrecht J; Below E; Alajati A; Sikic D; Breyer J; Bolenz C; Zengerling F; Erben P; Schwamborn K; Wirtz RM; Horn T; Nagy D; Toma M; Kristiansen G; Büttner T; Hahn O; Grünwald V; Darr C; Erne E; Rausch S; Bedke J; Schlack K; Abbas M; Zschäbitz S; Schwab C; Mustea A; Adam P; Manseck A; Wullich B; Ritter M; Hartmann A; Gschwend J; Weichert W; Erlmeier F; Hölzel M; Eckstein M
Clin Cancer Res; 2023 Apr; 29(8):1496-1505. PubMed ID: 36534531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]